1. History and introduction of Dong A pharmaceutical
Dong-A Pharmaceutical is the leading pharmaceutical company in Korea. Dong-A stands at the forefront of Korea's pharmaceutical industry; motivated by its respect for life and health to continuously innovate and develop products that enhance people's quality of life. We are working hard to grow internationally and become one of the world's most
Chapter 1. Indian Pharmaceutical Market Overview
1.1 Scale of Pharmaceutical Market
1.1.1 Domestic pharmaceutical market
India is among the fastest growing pharmaceutical markets in the world. The domestic pharmaceutical market recorded sales of US$ 7.3 billion in 2006 with a growth of 17.5 per cent over the previous year.
1.1.2 Pharmaceutical Industry
The Indian pharmaceutical industry
I. Introduction of Hanmi
Hanmi is pharmaceutical company spearheading innovation in life science. Hanmi was established by Lim,Sung Gi in 1973 based on mottoes –“Human Respect” & “Creation of Value”, Hanmi has endless exerted all its power for precious human life. For the purpose of the progress of pharmaceutical industry and the supply of highly qualified medicines with the most
REBATE?
Literally
Paying back a portion of the payment or interest to the payee
In the field of medicine
Pharmaceutical company pays back to the hospital
through negative market
Cause of Rebate in Korea
K-1. Special characteristics of Medical industry
Patients have no option in choice of drugs
Doctors have the incentive to use their
professionalism to maximize their p
to doctors who make decision about pharmaceutical prescription
The goal of this policy is increasing a sense of cost to doctor and improving medical treatment.
Characteristic
Doctors are able to get an incentive when they make a goal that follows the guide-line or expends some cost subject to budget.
Direct way: Affecting doctor’s income
Indirect way: Profit for clinics or patients
Founded 1926. 6.20
Wide range of product
-Pharmaceuticals, Household products, IT
Export API (Active Pharmaceutical Ingredients)
Levanex - domestically developed new ulcer drug
1. Overview
1980s
Recognized the potential of modern biotechnology
Early1990s
Stopped or reduced their research & efforts in biotechnology
Late 1990s
Only food and beverage enterprise, pharmaceutical and chemical companies invested significantly
Takeda Pharmaceutical Enterprise
focused on metabolic disorders, neurology, inflammation,
as well as oncology through its independe
pharmaceutical product is not valuable, inexpensive, easy to get.
Bargaining
Power of buyers
Low Before the prescription regulations buyers can get pills more easily.
But after prescription requirement regulations their option decreased.
Threat of
substitute
Low It can say “ there are no substitute”
Because of high regulations, product which have
devices
(1) Phytoncide
- Phyton : ‘Plants’
- Cide : ‘Kill’
- Found in early 20C
1) Market Attractiveness Analysis
3. Suitability
① Suitability of firm's vision
a. Vision : “We are committed to human healthcare”
-> Suitable
② Suitability of market & marketing mix
a. Pharmaceutical firm,
Customers = Wholesalers & Large hopitals
-> Unsuitable
Strengthening government regulation of the licensing
Economies of scale in the industry
2. Bargaining power of suppliers
(Low bargaining power of suppliers
in the pharmaceutical industry )
The presence of a number of providers
Long-term business confidence
Quality degradation due to cost savings
Sap containers / materials self -developed